deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
07 Mai 2009 - 2:32PM
PR Newswire (US)
REYKJAVIK, Iceland, May 7 /PRNewswire-FirstCall/ -- deCODE
genetics, Inc. (NASDAQ:DCGN) today announced that it will report
its first quarter 2009 financial results in a press release to be
issued on Monday, May 11, after the close of the market in New
York. The company will host a live webcast of its conference call
to discuss these results and recent operating highlights on
Tuesday, May 12, at 8am Eastern Daylight Time/ 12pm GMT/1pm British
Summer Time. The webcast can be accessed through the Investors page
of deCODE's website, http://www.decode.com/, or through
http://www.earnings.com/. Please log in to the webcast 15 minutes
prior to the scheduled start of the call. The call will be archived
for at least a week on each site. For those unable to listen to the
webcast because of company firewall or other issues, a digitized
audio replay will also be available by telephone from approximately
10am EDT on Tuesday, May 12 and for one week thereafter. The
dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and
+1-(320)-365-3844 for those calling from outside the U.S. The
access code is 100482. Any statements contained in this
presentation that relate to future plans, events or performance are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results, and the timing of events, to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating
to our ability to obtain sufficient financing to continue as a
going concern, the outcome of the review of the continued listing
of our common stock on The Nasdaq Stock Market, our ability to
develop and market diagnostic products, the level of third party
reimbursement for our products, risks related to preclinical and
clinical development of pharmaceutical products, including the
identification of compounds and the completion of clinical trials,
our ability to form collaborative relationships, the effect of
government regulation and the regulatory approval processes, market
acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships,
the effect of competitive products, industry trends and other risks
identified in deCODE's filings with the Securities and Exchange
Commission, including, without limitation, the risk factors
identified in our most recent Annual Report on Form 10-K and any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future
events or otherwise. Contacts: deCODE genetics Gisli Arnason
+354-570-1825 DATASOURCE: deCODE genetics Inc CONTACT: Contacts:
deCODE genetics, Gisli Arnason, +354-570-1825,
Copyright
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Decode Genetics (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Decode Genetics (MM)